Chad Weldy, MD, PhD
@chadweldy.bsky.social
240 followers 370 following 45 posts
Cardiologist and physician-scientist @Stanford | Instructor of Medicine | working to accelerate precision medicine through epigenetics and RNA editing https://profiles.stanford.edu/chad-weldy
Posts Media Videos Starter Packs
Reposted by Chad Weldy, MD, PhD
jengreitz.bsky.social
Excited for a major milestone in our efforts to map enhancers and interpret variants in the human genome:

The E2G Portal! e2g.stanford.edu

This collates our predictions of enhancer-gene regulatory interactions across >1,600 cell types and tissues.

Uses cases 👇

1/
chadweldy.bsky.social
Hey thanks! Hope you’re doing well!
chadweldy.bsky.social
There's a lot here and a lot more in the paper. But I get excited thinking about the potential. From rare to complex disease to novel mechanisms with real potential for a precision guided approach to therapy. A lot to do! @stanfordmedicine.bsky.social @stanforddeptmed.bsky.social
chadweldy.bsky.social
To then connect this back to humans, entirely grateful for collaborators @clintomics.bsky.social & Sander van der Laan where we investigated ISG activation and SMC modulation and plaque phenotype in the Athero-Express cohort, showing distinct relationships between ISG induction and calcification
chadweldy.bsky.social
Importantly, we define the cellular trajectory of MDA5 activation leading to vascular calcification and disease progression, an effect that can be entirely inhibited with simply haploinsufficiency of MDA5.
chadweldy.bsky.social
This MDA5 activation leads to increased plaque size due to increased SMC migration into the plaque with markedly increased vascular calcification.
chadweldy.bsky.social
But importantly, we show that with SMC ADAR1 haploinsufficiency, atherosclerosis studies reveal that MDA5 activation occurs in a cell type and context specific mechanism. MDA5 activation drives a distinct SMC cell state change.
chadweldy.bsky.social
In atherosclerosis - we show that SMCs appear to be enriched for these immunogenic RNA, and that as SMC undergo phenotypic modulation in both human and mouse there is significant activation of ISG genes, potentially suggestive of MDA5 activation
chadweldy.bsky.social
With homozygous deletion of ADAR1 in SMC, there is a loss of vascular integrity. Further single cell RNA sequencing reveals distinct ISG activation and cellular infiltration with critical receptor ligand interaction
chadweldy.bsky.social
Our work here gets at this mechanism.

We reveal a fundamental observation, that vascular SMC have a unique requirement for ADAR1 editing to prevent MDA5 activation.

SMC deletion of ADAR1 leads to severe phenotype within days and is entirely blocked with deletion of MDA5
chadweldy.bsky.social
In addition, rare LOF variants in MDA5 (IFIH1) have been found to be protective against CAD as well as other inflammatory disorders. This provides quite strong human genetic evidence to support ADAR1-dsRNA-MDA5 axis in CAD, but through what mechanism?
chadweldy.bsky.social
The big finding in 2022 by my colleagues Qin Li (now @upenn.edu and Billy Li @stanforduniversity.bsky.social)
was that beyond rare disease, common variants appear to regulate RNA editing (edQTLs), and these edQTLs predict numerous common inflammatory disorders, including CAD! t.co/t1i47lPlGG
chadweldy.bsky.social
Amazingly, mice that are deficient in ADAR1 are embryonic lethal, but dual knock out of ADAR1 and MDA5 essentially rescues the phenotype. In this case, the role of ADAR1 seems to be nearly entirely based on preventing MDA5 activation, less so the actual edit of the transcript
chadweldy.bsky.social
In rare disease, loss of ADAR1 causes a severe interferonopathy due to the build up of dsRNA and activation of the dsRNA receptor MDA5 (gene symbol IFIH1). Similarly, gain of function variants in MDA5 (IFIH1) cause the same disorders, including severe vascular calcification
chadweldy.bsky.social
RNA has the peculiar pattern of having long repetitive elements on either end, where these strands fold over on each other to make double strand RNA structures -> turns out this looks a lot like a dsRNA virus!

So why doesn't this dsRNA induce an antiviral response? ADAR1!
chadweldy.bsky.social
When ADAR editing occurs in the coding region of a transcript, it serves as an A -> G edit and can change protein function.

Even in coral and octopus in response to temperature changes of the ocean, whoa!

Although amazingly, the majority of editing sites are non-coding (hmm)
chadweldy.bsky.social
What is RNA editing and how does this relate to coronary artery disease??

There's a lot here but it's fascinating.

A to I editing is an under appreciated area of biology, where ADAR enzymes deaminate adenosine to inosine. Thousands of RNA molecules are edited all the time!
chadweldy.bsky.social
This work is exciting in that it defines an important area of vascular biology with key relevance to understanding genetic drivers of disease risk, couldn't have been done with out the amazing support of Tom Quertermous and all our amazing collaborators and team @stanfordmedicine.bsky.social
chadweldy.bsky.social
Through ChromBPNet analysis, by identifying the variants that affect chromatin accessibility in a vascular site specific manner, we identified that many of these variants land in key developmental TF motifs such as MEF2A, HAND2, as well as other regulatory TFs important in disease risk such as SMAD3
chadweldy.bsky.social
Not only can we reveal and predict variant effect on chromatin accessibility, but we define that effect varies by vascular site even within cell type
chadweldy.bsky.social
But how does this relate to human disease?? Through an awesome collaboration with the @anshulkundaje.bsky.social lab, we trained ChromBPNet models with scATACseq datasets for each cell type and vascular site, and predict human variant effect on a cell type/site basis @soumyakundu.bsky.social
chadweldy.bsky.social
Gene regulatory network analysis through integrated RNA and ATAC datasets across cell types and vascular sites reveal cell type and vascular site specific GRNs, this highlighted ascending fibroblast specific MEOX1
chadweldy.bsky.social
Vascular site specific epigenomic patterns are distinct for SMCs, fibroblasts, as well as endothelial cells, but importantly not macrophage cells. While developmental TFs a enriched there are thousands of distinct enhancer elements across vascular sites
chadweldy.bsky.social
Many enhancers correspond to developmental origin and highlight specific developmental transcription factors such as HAND2, GATA4, and HOX family members, suggestive of an epigenetic 'memory' of developmental origin